and thank you today business XXXX third Inhibikase's quarter And to financial Thank us joining review recent for results updates. Alex. you,
U.S. that the IkT-XXXXXX X Administration Food new On or system start for by multiple IkT-XXXXXX or programs. our of XXXXXX MSA. investigational announced our me or we for had Let reviewed treatment on the November drug and application atrophy providing update IND Drug
clinical hold a of have their like I hold on As events ongoing within use that MSA. Parkinson's a of observed the In IkT-XXXXXX only the that disease issued highlight IkT-XXXXXX-XXX mild have be XXX recorded trial, correspondence, in will letter adverse PD in serious and an they adverse or issued the XX no events. would days. and we FDA to Phase in review, in result two program email today the Xa official indicated clinical their
trial FDA XXX to plan We possible. the are X:X:X:X we for will patients the as working actively safety blinded dosing. were enrolled interim, to assessment based on as them a to and XX-week the with the concerns XX once-daily first the conduct In in randomize that understand agency's soon the resolve and
However, since once be the is completed had the hold FDA, with study to none of the lifted study, fully restarted. subject the initial discussions and XX need the to will patients clinical
were IkT-XXXXXX in was non-motor of and patients did in that reiterate high true the and enrolled quality healthy assessments like Xb tolerated this IkT-XXXXXX Society well exposure of showed over in study days of In central Movement patients Congress results addition, data September X from worsen These dosing. seven-day over in Phase study motor, at seven that presented would daily and to our of system not with CNS. persistent treatment dosing safe was into highlighted the the Moreover, with That in of IkT-XXXXXX I with Parkinson's Disorder that disease penetration and or disease. year. nervous life systemic both and volunteers
as soon priority the to development FDA is from resume of possible. resolve our concerns clinical or highest to IkT-XXXXXX Our questions any as
continuing are advance we the Turning to briefly of towards year. preclinical the IkT-XXXPro end by clinic our the efforts, to
formulation first for for Abelson a As the We in IkT-XXXPro received the mesylate developed our of FDA our Myelogenous Leukemia as to IND of safety clearance for imatinib stable-phase imatinib improved Chronic CML. improve as prodrug Tyrosine IkT-XXXPro FDA treatment of this Kinase or a is year. the reminder, inhibitor known application August
for As commonly from and imatinib that in is know, hematological bone cancers taken that marrow occurred from mutations the the in stomach. Abl mutations CK you for arises gastrointestinal kinase cancers or gastrointestinal
may If of formulation major or the that a up be potential reach could patients for higher side before reduce and gastrointestinal CML. effects the non-human times imatinib has that cytogenic improve in has In this people, prodrug and be preclinical X complete responses number administration Our alternative safer IkT-XXXPro X, observed primates to the in patients. oral studies, stable or following the gastrointestinal dosed phase patients occur tumor burdensome sustain event. than the in to inducing stromal adverse in CML potential
drug at administration. three to XX imatinib similar with to the study XX hours dose to efficacy study now safety female of study enroll IKT-XXXPro exposure are and receive XX a ages compared We a at The ascending of The a one who systemic drug. the mesylate, volunteers doses. evaluate dose approximately male single and IkT-XXXPro pharmacokinetic advancing XXX-milligram of identify and will of aim XX healthy post standard XXX will the the bio-equivalence of between into will profile also care
We occurred the expect of the patient during fourth quarter of first dosing the XXXX.
open update to financials. a the brief questions, want on provide Before I to our call we
per cash XXXX approximately loss we had share. $X.X As equivalents approximately the September for marketable of cash, $XX.X and or quarter was Net securities. in million XX, million $X.XX
on through our marketable subject and fund to cash, our cash capital to FDA requirements existing program. securities February XXXXXX from will We outcomes with the discussions expect the expenditure operations XXXX, normal be sufficient and equivalents our
the open the continue fully year. of on mission to long-term end our to the call expect As Inhibikase we initiate study we our to remainder shareholders to bioequivalence improve IkT-XXXPro want our their by our remain And year, of programs. for lives clinical I provide to IkT-XXXXXX additionally, look to neurodegenerative questions. of as and the the the devastating updates I would appropriate for suffering hold to from Operator? will now for XXX continued thank the as of patients we committed diseases. like support oncological we of
